BioCentury
ARTICLE | Company News

Morphochem, Aventis deal

March 26, 2001 8:00 AM UTC

Morphochem and AVE’s Aventis Pharma AG subsidiary (Frankfurt, Germany) will develop compounds against an undisclosed AVE diabetes target using Morphochem’s high throughput chemical genomics technology...